Boehringer Ingelheim India has signed a landmark MoU with the National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, including its Centre of Excellence for Novel Drug Delivery Systems (CoE-NDDS), to bolster pharmaceutical innovation in this country.

 

The signing took place at the Department of Pharmaceuticals, with Manoj Joshi, Secretary, Department of Pharmaceuticals, in attendance. Also present were Awadhesh Kumar Choudhary, Senior Economic Advisor, and Anugraha P, Director, Department of Pharmaceuticals.

 

The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies, novel drug delivery systems, joint research initiatives, academic exchanges, and capability-building programs.

 

As part of the agreement, Boehringer Ingelheim will provide NIPER Raebareli access to opnMe, its open science portal designed to connect researchers and institutions to accelerate innovation in healthcare. The partnership will also explore symposia, conferences, short-term courses, and scholar engagement to strengthen research, learning, and scientific exchange.

 

Meenal Gauri, Managing Director of Boehringer Ingelheim India, said, “India is entering an important phase in its pharmaceutical journey, moving from scale-led growth to innovation-led impact. At Boehringer Ingelheim, we believe progress in healthcare is accelerated when industry, academia, and public institutions come together. 

 

"This MoU with NIPER Raebareli reflects our commitment to strengthening scientific capability and supporting collaborations that can contribute to better health outcomes for patients and communities.”

 

Prof. Shubhini A Saraf, Director of NIPER Raebareli, added, “This MoU supports our vision of advancing pharmaceutical education and research while enabling opportunities for students and researchers to contribute to areas of emerging importance such as novel drug delivery systems and community health solutions. We look forward to working with Boehringer Ingelheim to create meaningful opportunities for students and researchers and to contribute to India’s innovation ecosystem.”

 

The partnership aligns with India’s broader healthcare goals, as the government actively supports the transition from a volume-driven, generic-focused pharmaceutical sector to a high-value, innovation-led ecosystem.